ProMetic Life Sciences has selected Alpha1-Antitrypsin (AAT) as its second plasma-derived therapeutic to develop and commercialise the product to address AAT deficiency.
The company's PPPS process confirmed to produce AAT with three-fold yield advantage over existing industry average.
AAT will be manufactured in ProMetic's Laval facility and Hematech's future facility in Taipei. An NDA is expected to be filed in 2014 with expected market entry in 2016/2017.
ProMetic president and CEO Pierre Laurin said, "The current dire need for AAT and potential growing demand far exceed industry capacity.
"Our superior production yield provides ProMetic with a significant strategic commercial advantage and partnering opportunities."
AAT Deficiency leads to a lack of AAT in the blood which can then result in serious lung disease in adults and/or liver disease at any age.